As of today (2024-04-25), icad's share price is $1.56. icad's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $0.95. Hence, icad's Price to Tangible Book Ratio of today is 1.65.
The historical rank and industry rank for icad's Price-to-Tangible-Book or its related term are showing as below:
ICAD'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.62 Med: 6.21 Max: 14.59
Current: 1.64
During the past 13 years, icad's highest Price to Tangible Book Ratio was 14.59. The lowest was 1.62. And the median was 6.21.
ICAD's Price-to-Tangible-Book is ranked better than 67.81% of 702
companies
in the Medical Devices & Instruments industry
Industry Median: 2.62
vs ICAD: 1.64
A closely related ratio is called PB Ratio. As of today, icad's share price is $1.56. icad's Book Value per Sharefor the quarter that ended in Dec. 2023 was $1.27. Hence, icad's P/B Ratio of today is 1.23.
icad Price-to-Tangible-Book Historical Data
The historical data trend for icad's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of icad's Price-to-Tangible-Book
For the Medical Devices subindustry, icad's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
icad's Price-to-Tangible-Book Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, icad's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where icad's Price-to-Tangible-Book falls into.
icad Price-to-Tangible-Book Calculation
icad's price-to-tangible-book ratio for today is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
icad Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of icad's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company reports in two segments: Detection and Therapy. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. In the Therapy segment, the Company offers the Xoft System, an isotope-free cancer treatment platform technology. The Xoft System can be used for the treatment of early-stage breast cancer, endometrial cancer, cervical cancer and nonmelanoma skin cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ICAD has been successfully added to your 